ResearchPCRX
PCRX: FY25 Deep Dive
Published 1 min read
Summary
Pacira BioSciences FY25 at $726M. NI $7M; EPS $0.16.
FY25 revenue $726M; OI $28M; NI $7M; EPS $0.16.
Pacira BioSciences FY25 (Dec 31, 2025) at $726M revenue. OpInc $28M; NI $7M; EPS $0.16. Pharma — Pain Mgmt.
